替米沙坦对糖尿病合并高血压患者脂联素及胰岛素抵抗的影响

Efficacy of telmisartan for control of serum levels of adiponectin and TNF-α in patients with type 2 diabetes and hypertension

目的:观察替米沙坦治疗2型糖尿病伴高血压患者后血清脂联素的变化及其对胰岛素抵抗的影响。方法:42例2型糖尿病伴高血压患者,口服替米沙坦80～160 mg,qd,共12周,观察治疗前和治疗后的血清脂联素、肿瘤坏死因子(TNF-α)浓度,并观察血压、血脂和胰岛素抵抗指数(IRI)水平。结果:替米沙坦治疗后收缩压和舒张压明显下降(P＜0．05),血清脂联素浓度明显升高(P＜0．05),TNF-α浓度明显下降(P＜0．05);IRI下降(P＜0．05)。结论:替米沙坦在升高血清脂联素浓度和降低TNF-α浓度的同时,具有改善胰岛素抵抗的作用。

Objective： To evaluate the efficacy of telmisartan for the management of serum levels of adiponectin and TNF-α in patients with type 2 diabetes and hypertension. Methods： 42 patients with type 2 diabetes associated with hypertension orally received telmisartan 80-160 mg·d^-1 for 12 weeks. The effectiveness of the therapy was assessed based on tile improvements of BP, levels of adiponectin, TNF-α, blood glucose and insulin after the treatment. Insulin resistance index was measured. Results： The telmisartan-treated patients significantly experienced reductions of BP, TNF-α level and insulin resistance index （P〈0.05 ） and escalation of adiponectin level （P〈0.05 ）. Conclusion ： Telmisartan offered a therapeutic option for patients with type 2 diabetes associated with hypertension.